The gold standard for early detection of prostate cancer, PSA, has recently come under fire for its high rate of false positives. Virginia Hughes investigates some of the researchers hunting for better alternatives and asks whether their promises of creating viable—and profitable—biomarker tests will ever be realized.
This is a preview of subscription content, log in via an institution to check access.
References
Stamey, T.A. et al. N. Engl. J. Med. 317, 909–916 (1987).
Getzenberg, R.H. et al. Cancer Res. 51, 6514–6520 (1991).
Leman, E.S. et al. Urology 69, 714–720 (2007).
Brown, D. The Washington Post 26 April 2007, A3.
Underwood, A. Newsweek <http://www.newsweek.com/id/35171> (26 April 2007).
Kramer, B.S. et al. Ann. Intern. Med. 119, 914–923 (1993).
Smith, D.S. et al. Cancer 80, 1852–1856 (1997).
Andriole, G.L. et al. N. Engl. J. Med. 360, 1310–1319 (2009).
Schröder, F.H. et al. N. Engl. J. Med. 360, 1320–1328 (2009).
Esserman, L. et al. J. Am. Med. Assoc. 302, 1685–1692 (2009).
Diamandis, E.P. Clin. Biochem. 40, 1437–1439 (2007).
Shariat, S.F. et al. Clin. Cancer Res. 14, 3785–3791 (2008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hughes, V. Markers of dispute. Nat Med 15, 1339–1342 (2009). https://doi.org/10.1038/nm1209-1339
Issue Date:
DOI: https://doi.org/10.1038/nm1209-1339
- Springer Nature America, Inc.
This article is cited by
-
Ribonuclease 4 is associated with aggressiveness and progression of prostate cancer
Communications Biology (2022)